Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · IL0011319527 TA Manufacturing
Open in API
Filings indexed 485 across all filing types
Latest filing 2021-02-10 Report Publication Anno…
Country IL Israel
Listing TA ENLV

About Enlivex Therapeutics Ltd.

https://enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. It is focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to treat immune system dysregulation. The therapy works by reprogramming macrophages to resolve hyper-inflammation. Enlivex is evaluating Allocetra™ in clinical trials for the treatment of multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis. The product candidate offers flexible administration options, including systemic intravenous infusion and targeted local injections.

Recent filings

Filing Released Lang Actions
Announces $10 Million Bought Deal Offering of Ordinary Shares
Report Publication Announcement Classification · 1% confidence The document is a filing submitted to the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). It explicitly states, "Attached hereto is a report on *FWP* *FWP_09022021_isa.pdf*". The document itself is very short (1817 characters) and serves primarily to announce the availability of an attached report (FWP, likely Foreign Private Issuer Filing or similar regulatory document). According to Rule 2, when a document is short and announces the publication of another report, it should be classified as a Report Publication Announcement (RPA). It is not the full financial report (10-K or IR) or a specific type like ER or DIV.
2021-02-10 English
Prospectus Supplement to Prospectus dated June 21, 2019
Capital/Financing Update Classification · 1% confidence The document explicitly states it is a "preliminary prospectus supplement" to an accompanying prospectus, filed with the Securities and Exchange Commission (SEC). It details an offering of ordinary shares, including pricing tables, underwriting information, and a table of contents for the supplement and prospectus. This structure—a supplement offering securities registered on a shelf registration statement (Form F-3 mentioned in the text)—is characteristic of a securities offering document. Since it is a document related to the offering of securities, it falls under the category of Capital/Financing Update (CAP) or potentially a specific type of registration statement filing. However, given the context of offering securities and the detailed financial/offering structure, 'CAP' (Capital/Financing Update) is the most appropriate fit among the provided options, as it directly relates to fundraising activities. It is not a standard 10-K, AR, ER, or IR. It is a document soliciting investment, which is a financing activity.
2021-02-10 English
Prospectus Supplement to Prospectus dated June 21, 2019
Report Publication Announcement Classification · 1% confidence The document explicitly states it is an 'Other Report or Announcement' filed under 'Regulation 5 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000'. Crucially, it mentions that attached is a report on '*Form 424B5*'. Form 424B5 is typically used in the US for filing prospectuses related to the offering of securities, often following an S-1 registration. Since this document is a short announcement (1826 chars) stating that another specific report (the 424B5 filing) is attached or referenced, it fits the definition of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given the specific nature of the attachment (a prospectus filing), and the fact that 'CAP' (Capital/Financing Update) is a strong candidate, I must check the definitions. A 424B5 filing relates directly to capital raising/offering. However, the document itself is merely the *announcement* of that filing, not the detailed financing document. Since RPA is for announcing the publication of reports, and RNS is the general fallback, I will evaluate if 'CAP' is better. 'CAP' is for updates on fundraising/financing activities. This document announces a filing related to a security offering. Because it is an announcement of a filing rather than the financing document itself, RPA or RNS is more appropriate based on Rule 2. If it were the full 424B5, it would be CAP. As it is the cover sheet announcing the 424B5, RPA is the best fit for announcing the publication of a report, although RNS is also plausible as a catch-all for foreign regulatory filings.
2021-02-10 English
TERMINATION OF ATM AGREEMENT FROM 22.2.20
Regulatory Filings Classification · 1% confidence The document explicitly states 'Form Type* 6-K' in the metadata section and 'Form 6-K' in the main body. A Form 6-K is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934. This form is used for material, current information that is required to be reported to shareholders in the home country or exchange, but which is not covered by the periodic reports (like 20-F). Since there is no specific category for Form 6-K among the provided definitions (AGM-R, 10-K, AR, etc.), and it represents a general, current regulatory disclosure, the most appropriate fallback category is 'Regulatory Filings' (RNS). The document is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K), but rather a specific SEC filing type.
2021-02-10 English
TERMINATION OF ATM AGREEMENT FROM 22.2.20
Report Publication Announcement Classification · 1% confidence The document is very short (1754 characters) and explicitly states, "Attached hereto is a report on *6-k* *6k09022021_isa.pdf*". This structure indicates that the document itself is an announcement about the publication of another report (a 6-K filing, which is typically an immediate report filed with the SEC by foreign private issuers). According to Rule 2, when a document is short and announces the attachment or publication of a formal report, it should be classified as a Report Publication Announcement (RPA). The presence of the Israel Securities Authority and TASE headers confirms it is a regulatory filing, but the content points specifically to the announcement mechanism rather than the full report content.
2021-02-10 English
Positive Top-Line Results from Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients and Provides a Program update
Regulatory Filings Classification · 1% confidence The document explicitly states it is a "Form 6-K" filed with the "UNITED STATES SECURITIES AND EXCHANGE COMMISSION" for the month of "February 2021". Form 6-K is the standard filing for a Foreign Private Issuer to report material information to the SEC, often including press releases about material events. The content is a press release announcing positive top-line results from a Phase II clinical trial for a drug (Allocetra™) in COVID-19 patients. This type of material event disclosure by a foreign private issuer is typically filed on Form 6-K. Since Form 6-K is not explicitly listed in the provided codes, and this document is a formal regulatory filing reporting a material event (clinical trial results), it falls best under the general category for regulatory filings that don't fit elsewhere, which is RNS (Regulatory Filings). Although it contains an Earnings Release (ER) style announcement, the wrapper is the 6-K filing itself, making RNS the most appropriate classification for the filing type.
2021-02-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.